Skip to Content

Can a PDE4-inhibitor be the next approved drug for the treatment of hidradenitis suppurativa?

In this MEDtalk, Elisabeth H. Taudorf, MD, Zealand University Hospital takes a deep dive into a patient case with severe HS. The patient was treated with a PDE-4 inhibitor. In this phase-II study, the focus was on reduced pain and increased quality of life following treatment with the pde4-inhibitor.

Elisabeth Hjardem Taudorf

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top